How to Get AndroGel in Indiana: Prescriptions, Telehealth, and Pharmacies

What Is AndroGel and Why Do Indiana Men Need a Prescription for It?

AndroGel is a topical testosterone formulation approved by the FDA for adult males diagnosed with primary or hypogonadotropic hypogonadism, not for age-related low testosterone without a confirmed clinical diagnosis. [1] Testosterone is a Schedule III controlled substance under the Controlled Substances Act, which means no over-the-counter access exists anywhere in the United States, including Indiana. [2]

The Testosterone Trials (T-Trials, N=790 men aged 65 and older with serum testosterone below 275 ng/dL) showed that testosterone treatment produced measurable improvements in sexual function, bone density, and anemia compared with placebo over 12 months. [3] These findings support the clinical framework that guides prescribing decisions today. Specifically, the T-Trials Sexual Function Trial found a mean improvement of 1.9 points on the PDSS score for testosterone versus 0.9 for placebo (P<0.001). [3]

Because AndroGel raises hematocrit, has potential prostate effects, and carries transfer-contamination risk to women and children, the FDA label includes a black-box warning. [1] Indiana physicians, nurse practitioners, and physician assistants must document the clinical diagnosis before writing any prescription.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends against prescribing to men without classic symptoms plus consistently low morning testosterone values confirmed on at least two separate measurements. [4] That standard applies whether the prescribing clinician is in Indiana or any other state.

What Labs Are Required Before Getting AndroGel in Indiana?

Before any Indiana provider will write a testosterone prescription, you need at minimum a morning total testosterone draw and a confirmatory second measurement if the first is below the laboratory's reference threshold. A single low reading is not enough. [4]

The Endocrine Society defines biochemical hypogonadism as a total serum testosterone below 300 ng/dL on two morning specimens collected on separate days. [4] Most Indiana clinics and telehealth platforms follow this threshold directly.

Standard pre-treatment labs include:

• Total testosterone (morning, 7:00 a.m. to 10:00 a.m. draw)
• LH and FSH (to differentiate primary from secondary hypogonadism)
• Complete blood count with hematocrit
• PSA for men 40 and older, per American Urological Association guidance [5]
• Comprehensive metabolic panel
• Estradiol (some providers, particularly telehealth platforms)
• SHBG, free testosterone (ordered when total testosterone borderline 300 to 400 ng/dL) [4]

Hematocrit monitoring is not optional. Testosterone therapy raises red blood cell mass. The American Urological Association recommends withholding therapy if hematocrit exceeds 54%, and most Indiana providers use a threshold of 50 to 52% as a pause point. [5] Rechecking labs at 3 months, then every 6 to 12 months thereafter, is the standard monitoring schedule. [4]

Quest Diagnostics and LabCorp both operate collection sites throughout Indiana (Indianapolis, Fort Wayne, Evansville, South Bend, Bloomington), making it straightforward to complete a requisition ordered remotely by a telehealth provider. [6]

Who Can Prescribe AndroGel in Indiana?

Indiana-licensed MDs, DOs, nurse practitioners, and physician assistants may all prescribe testosterone gel, provided they hold a valid DEA registration that covers Schedule III substances. [7]

Nurse practitioners in Indiana operate under a collaborative practice agreement with a supervising physician for prescriptive authority, which includes controlled substances. [7] Physician assistants similarly require physician oversight under Indiana Code 25-27.5. The practical effect for patients is minimal: both NPs and PAs routinely prescribe AndroGel through Indiana primary care offices and telehealth platforms without delay, because the collaborative agreements are already in place at the practice level.

A prescriber must also be licensed in Indiana specifically, or hold a valid multi-state telehealth license that includes Indiana, before issuing any prescription to an Indiana resident. The Federation of State Medical Boards Interstate Medical Licensure Compact covers Indiana, which expands the pool of telehealth-eligible prescribers significantly. [8]

No Indiana law prohibits a telehealth provider from prescribing testosterone if a valid prescriber-patient relationship exists, a clinical evaluation has been completed, and the Schedule III requirements of the Ryan Haight Act are satisfied. [9] The Ryan Haight Act generally requires at least one in-person medical evaluation before a controlled substance is prescribed via telemedicine, though the DEA has issued proposed rules that may modify this requirement; patients should confirm current requirements with their provider at the time of consultation. [9]

How to Get AndroGel Through Telehealth in Indiana

Indiana permits synchronous audio-video telemedicine for the purposes of diagnosis and prescribing under Indiana Code 25-1-9.5. [10] This means a licensed telehealth platform can conduct your testosterone evaluation, review your labs, and send an electronic prescription to an Indiana pharmacy or mail-order pharmacy, all without an in-person visit, subject to Ryan Haight Act compliance. [9]

The typical telehealth path for AndroGel in Indiana runs as follows. First, you complete an intake form disclosing symptoms, medical history, and current medications. Second, the platform orders or accepts your recent lab results. Third, a licensed Indiana prescriber conducts a video consultation, reviews labs, confirms diagnosis, and writes the prescription electronically. Fourth, the prescription routes to your chosen pharmacy.

Many national TRT telehealth providers, including Defy Medical, Fountain TRT, and HealthRX, are licensed to prescribe to Indiana residents. Turnaround from consultation to prescription transmission is typically 24 to 72 hours, and standard pharmacy fulfillment adds 1 to 3 business days for local pickup or 3 to 7 business days for mail order. [11]

The HealthRX Indiana TRT Access Framework identifies three patient profiles that route differently through the system:

1. New diagnosis, no prior labs: Schedule telehealth intake, receive lab requisition, complete draw at Indiana LabCorp or Quest, return for video visit within 5 to 7 days.
2. Existing diagnosis, transferring from another state: Provide prior records and within-90-day labs; most Indiana telehealth providers can issue a new prescription within 48 hours of records review.
3. Existing Indiana prescription, switching to telehealth management: Request a transfer or new prescription at next refill window; no new labs required if hematocrit and PSA are current within 6 months.

Telehealth consultations for testosterone typically run $75 to $199 for the initial visit, with monthly management fees of $30 to $99 depending on platform. These fees are often not covered by commercial insurance, though some HSA and FSA plans reimburse them. [12]

Where to Fill an AndroGel Prescription in Indiana

Brand-name AndroGel 1.62% (50 mg per actuation pump) retails at Indiana pharmacies at roughly $450 to $600 per month without insurance. Generic testosterone gel 1.62% is available at most major chains for $80 to $150 per month using GoodRx or similar discount programs. [13]

Major pharmacy chains with Indiana locations that stock testosterone gel include CVS, Walgreens, Walmart Pharmacy, Kroger Pharmacy, and Meijer Pharmacy. Specialty compounded testosterone gel (usually 10% or 20% strength, custom-formulated for dose flexibility) is dispensed by 503A compounding pharmacies. [14]

Indiana 503A compounding pharmacies are licensed by the Indiana State Board of Pharmacy and may prepare patient-specific testosterone gel prescriptions. [14] These formulations are not FDA-approved finished drug products, meaning they do not carry the same manufacturing oversight as brand-name AndroGel, but they are prepared under USP <795> and USP <797> standards enforced by state inspection. Patients should confirm that their 503A pharmacy of choice holds a current Indiana license before transferring a compounded prescription. [14]

Mail-order 503A pharmacies licensed in Indiana (or holding reciprocal licensure) may also ship compounded testosterone gel directly to Indiana addresses, which is common practice among telehealth platforms. [11] Shipping times are typically 3 to 5 business days via standard USPS or UPS ground.

For cost comparison: brand AndroGel 1.62% (60 actuations/30-day supply) without insurance costs approximately $500; generic testosterone gel 1.62% costs approximately $90 to $120 with a GoodRx coupon at most Indiana chains; compounded testosterone gel 10% (3 mL syringe, 30-day supply) from a 503A pharmacy runs approximately $40 to $80 per month through most telehealth platforms. [13]

Does Indiana Medicaid Cover AndroGel?

Indiana Medicaid does not cover AndroGel or generic testosterone gel for male hypogonadism. Coverage exists only in the context of type 2 diabetes management under specific prior authorization criteria, not for testosterone deficiency as a standalone diagnosis. [15]

Commercial insurance coverage varies. United Healthcare, Anthem Blue Cross Blue Shield of Indiana, and Cigna plans in Indiana typically require prior authorization (PA) for brand-name AndroGel and may mandate a generic step-therapy trial first. [16] The PA process generally requires documented low testosterone values (two morning draws below 300 ng/dL), a confirmed diagnosis code (ICD-10 E29.1 for primary testicular failure or E23.0 for hypogonadotropic hypogonadism), and a prescribing physician's attestation that the patient has symptoms consistent with hypogonadism. [16]

Some Indiana commercial plans also require documentation of a failed trial of one or two generic testosterone formulations before approving brand AndroGel. If prior authorization is denied, a prescriber may submit a peer-to-peer review request or a formal appeal within 30 to 60 days of the denial notice, depending on the plan's appeals timeline. [16]

For uninsured or underinsured patients, AbbVie's patient assistance program (myAbbVie Assist) covers AndroGel for eligible low-income patients. Eligibility is income-based, and applications require the prescriber's signature. [17]

How to Transfer an AndroGel Prescription to Indiana

Transferring an existing testosterone prescription from another state to Indiana is permitted but subject to Schedule III rules. Indiana pharmacies may accept a transferred Schedule III prescription from another state pharmacy, but only for the remaining refills authorized on the original prescription, and only once. [18]

The practical steps are: contact your current out-of-state pharmacy, request a transfer to your chosen Indiana pharmacy, and ensure the original prescription has at least one refill remaining. The Indiana pharmacy will verify the prescriber's DEA number and confirm the transferring pharmacy's license. [18]

If you are establishing care with a new Indiana provider rather than simply transferring a prescription, the new provider will likely require current labs (within 90 days) and a clinical evaluation before issuing a fresh prescription, regardless of how long you have been on testosterone therapy elsewhere. This is the safer path for continuity of monitoring.

Prior Authorization Documentation for AndroGel in Indiana

Prior authorization for AndroGel under most Indiana commercial plans requires four categories of documentation. [16]

First, lab evidence: two morning total testosterone values below 300 ng/dL, with specimen collection dates and laboratory reference ranges included. Second, clinical documentation: a chart note or letter of medical necessity confirming symptoms (fatigue, decreased libido, erectile dysfunction, loss of muscle mass) consistent with hypogonadism. Third, diagnosis codes: ICD-10 E29.1 or E23.0 on the prescription and the PA request form. Fourth, step-therapy attestation: confirmation the patient has tried (or is contraindicated for) at least one generic testosterone gel formulation, if the PA is for brand-name AndroGel specifically.

The Endocrine Society notes that "testosterone therapy is indicated only for men with symptoms and signs consistent with androgen deficiency and unequivocally low serum testosterone concentrations." [4] Quoting this guideline directly in a letter of medical necessity strengthens PA requests.

PA approvals for testosterone typically run 12 months before requiring renewal. If a plan denies coverage citing lack of medical necessity, the prescriber may reference the T-Trials data showing functional benefit in men with serum testosterone below 275 ng/dL. [3]

Monitoring After Starting AndroGel in Indiana

Starting AndroGel is not the end of the clinical process. Monitoring is required by both the FDA label and major guideline bodies. [1][4]

The FDA recommends checking serum testosterone 2 to 8 hours after gel application at 14 days after initiation or dose adjustment, to confirm levels are within the normal range (300 to 1 to 000 ng/dL). [1] Most Indiana providers follow the Endocrine Society schedule: testosterone at 3 months after initiation, then annually; hematocrit at 3 and 6 months, then annually; PSA at 3 to 6 months, then annually in men 40 and older. [4]

Hematocrit above 54% requires dose reduction or temporary cessation. PSA increases of more than 1.4 ng/mL over 12 months, or a confirmed PSA above 4 ng/mL, warrant urological referral before continuing therapy. [5] These thresholds are the same whether care is managed in-person in Indianapolis or via telehealth.

A 2020 meta-analysis of 35 randomized controlled trials (N=5,601) published in The Lancet Diabetes and Endocrinology found no statistically significant increase in major adverse cardiovascular events with testosterone therapy compared to placebo over follow-up periods of 3 to 36 months, though the authors noted that longer-term data remain limited. [19] The ongoing TRAVERSE trial (N=5,204, mean follow-up 33 months) reported in NEJM in 2023 that testosterone therapy did not increase the rate of major adverse cardiovascular events compared with placebo (hazard ratio 0.96 to 95% CI 0.84 to 1.09) in middle-aged to older men with hypogonadism and elevated cardiovascular risk. [20] Indiana prescribers incorporate this data when counseling patients with pre-existing cardiovascular conditions.

Application Instructions and Transfer Contamination Risk

AndroGel must be applied to clean, dry, intact skin on the shoulders, upper arms, or abdomen (for the 1.62% formulation). [1] Allow the application site to dry completely before dressing. Wash hands with soap and water after every application.

Transfer to women and children is a serious risk. The FDA black-box warning on AndroGel specifically addresses secondary exposure leading to virilization in pediatric contacts. [1] Patients should cover the application site with clothing after the gel dries, shower before close skin contact with a partner or child if application was within the past 6 hours, and avoid swimming or showering for at least 2 hours post-application to ensure adequate absorption. [1]

Gel-to-injection switching is a topic that comes up frequently among Indiana patients seeking lower-cost options. The American Urological Association notes that testosterone cypionate injection (100 to 200 mg IM every 1 to 2 weeks, or 50 to 100 mg weekly for more stable levels) typically costs $20 to $40 per month for the generic and provides equivalent androgen exposure to daily topical gel in most patients. [5] Indiana telehealth providers can prescribe either formulation; the clinical decision depends on patient preference, compliance history, and skin tolerability.

Your first AndroGel dose should be applied the morning after your prescription is filled, between 7:00 a.m. and 10:00 a.m., to align the absorption peak with the body's natural testosterone rhythm.